stoxline Quote Chart Rank Option Currency Glossary
  
Adagene Inc. (ADAG)
1.82  0.195 (12%)    05-23 16:00
Open: 1.55
High: 1.86
Volume: 78,850
  
Pre. Close: 1.625
Low: 1.55
Market Cap: 69(M)
Technical analysis
2025-05-23 4:45:45 PM
Short term     
Mid term     
Targets 6-month :  2.17 1-year :  2.53
Resists First :  1.86 Second :  2.17
Pivot price 1.67
Supports First :  1.55 Second :  1.36
MAs MA(5) :  1.68 MA(20) :  1.63
MA(100) :  1.76 MA(250) :  2.24
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  60.4 D(3) :  52.1
RSI RSI(14): 60.6
52-week High :  3.58 Low :  1.32
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ADAG ] has closed below upper band by 5.3%. Bollinger Bands are 8.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.86 - 1.87 1.87 - 1.88
Low: 1.53 - 1.54 1.54 - 1.55
Close: 1.8 - 1.82 1.82 - 1.83
Company Description

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Headline News

Fri, 23 May 2025
Adagene (NASDAQ:ADAG) Trading Down 2.1% – Here’s Why - Defense World

Thu, 22 May 2025
New Clinical Data: Adagene's ADG126 Achieves Breakthrough 29% Response Rate in Hard-to-Treat Colorectal Cancer - Stock Titan

Mon, 28 Apr 2025
Adagene Appoints John Maraganore, Ph.D. as Executive Advisor - GlobeNewswire

Wed, 23 Apr 2025
Adagene Announces Upcoming Poster Presentation on Masked - GlobeNewswire

Mon, 07 Apr 2025
Adagene Reveals New Oncology Strategy: CEO Set for Major Investor Presentation - Stock Titan

Mon, 24 Mar 2025
Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 47 (M)
Held by Insiders 1.711e+007 (%)
Held by Institutions 4.6 (%)
Shares Short 67 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -3.523e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -17 %
Return on Assets (ttm) 82.3 %
Return on Equity (ttm) -22 %
Qtrly Rev. Growth 103200 %
Gross Profit (p.s.) -143.12
Sales Per Share -90.51
EBITDA (p.s.) 169180
Qtrly Earnings Growth -0.8 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -30 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.03
Price to Cash Flow 1.03
Stock Dividends
Dividend 0
Forward Dividend 39380
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android